SALIVA-MRD - patient-near saliva sampling for prevention, early detection and molecular surveillance of oral cancer
| Reference number | |
| Coordinator | Uppsala universitet - Uppsala universitet Inst immunologi genetik & patologi |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | November 2026 - November 2028 |
| Status | Ongoing |
| Venture | 2026-01505-en |
| Call | Collaborative projects for healthy and resilient communities |
Purpose and goal
SALIVA-MRD aims to develop and evaluate a scalable saliva-based platform for two clinical needs: early detection of oral cancer in patients with oral leukoplakia through analysis of cancer-associated protein signatures and molecular detection of recurrence after treatment of oral squamous cell carcinoma through analysis of circulating tumor DNA. The project combines patient-near saliva sampling with advanced molecular analysis to enable earlier diagnosis and improved follow-up.
Expected effects and result
The project will deliver validated sampling and analytical workflows, clinical pilot data and a plan for further multicenter validation and implementation. The results will provide knowledge on the feasibility and clinical utility of saliva-based biomarkers for oral cancer monitoring. In the long term, the project is expected to contribute to development of a sampling routine that leads to earlier detection, more accessible follow-up and better conditions for risk-adapted care in oral cancer.
Planned approach and implementation
The project develops and evaluates saliva-based risk monitoring of oral leukoplakia via innovative saliva sampling (SampleFacts AB) and proteomic analysis (Uppsala University), and molecular follow-up after treatment of oral squamous cell carcinoma by sensitive tumor DNA detection (Rarity Bioscience AB and Uppsala University). Clinical pilots will be done within established patient care pathways (Region Uppsala) supported by a national network. The project is coordinated by Uppsala University.